Results 1 to 10 of about 3,574 (108)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population

Cancer Medicine, 2023
Objective Dihydropyrimidine dehydrogenase (DPYD) genotype is closely associated with fluoropyrimidine (FP)‐induced toxicities in Caucasian population and European Medicines Agency now recommends DPYD genotype‐based FP dosing strategy.
Masashi Kanai, Tetsuo Touyama
exaly   +2 more sources

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland

Frontiers in Pharmacology, 2022
The implementation of pharmacogenetic testing into clinical practice has been a slow process so far. Here, we review the implementation of pre-treatment testing of dihydropyrimidine dehydrogenase gene (DPYD) risk variants to prevent early-onset ...
Carlo Rodolfo Largiadèr, Stefan Aebi, Ursula Amstutz   +2 more
exaly   +3 more sources

Genetic Variants Associated with Fluoropyrimidine-Induced Toxicity in Real-World Patients After Pre-Emptive DPYD Pharmacogenetic Testing [PDF]

Pharmaceuticals
Background/Objectives: As a treatment, fluoropyrimidines are often associated with early moderate-to-severe toxicity. Although pre-emptive DPYD genotyping enables genotype-guided dosing, significant adverse events still occur in patients classified as ...
María Rodríguez-García, Sara Salvador-Martín, Mariam Stephanie Rojas Piedra, Adrián Bravo, María Vidal, Carolina Figueras Gutierrez, Joan Maurel, Luis A. López-Fernández, Mercè Brunet   +8 more
doaj   +2 more sources

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy [PDF]

Clinical and Translational Science
Fluoropyrimidines are a vital component of chemotherapy regimens. Deleterious DPYD variants reduce activity of dihydropyrimidine dehydrogenase, the rate‐limiting enzyme of fluoropyrimidine catabolism, resulting in reduced fluoropyrimidine clearance and ...
Nihal El Rouby, Christina L. Aquilante, Salma A. Bargal, Larisa H. Cavallari, Julio D. Duarte, Kelly Gunderson, Tinashe Mazhindu, Mohamed Nagy, Xiaoyan Nie, D. Grace Nguyen, Jai N. Patel, Todd C. Skaar, D. Max Smith, Sony Tuteja, Ron H. N. vanSchaik, J. Kevin Hicks, The PGRN Implementation Working Group   +16 more
doaj   +2 more sources

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study [PDF]

Frontiers in Pharmacology
Introduction: Deficiency of the dihydropyrimidine dehydrogenase enzyme can result in capecitabine-related toxicity due to genetic alterations in the DPYD gene, leading to complete or partial DPD deficiency and poor or intermediate metabolizer phenotypes.
Hemavathi Baskarane, Mohit Kumar Divakar, Akhil P. Santhosh, Kriti Pallavi, Vishakha Hooda, Vamsi Krishna Yenamandra, Saran Kumar, Vrajesh Shetty, Jahnavi Banotra, Ishaan Gupta, Shilpi Minocha, Pranay Tanwar, Atul Sharma, Payal Vasudeva, Akash Kumar, R. Chethan, Sameer Bakhshi, Atul Batra   +17 more
doaj   +2 more sources

Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy [PDF]

Medical Sciences
Background: The DPYD gene encodes dihydropyrimidine dehydrogenase (DPD), an enzyme essential for metabolising chemotherapeutic agents such as capecitabine, 5-fluorouracil (5-FU), and tegafur.
Bahaaeldin Baraka, Navin Mathiyalagan, Maryam Al-Ani, Gaurav Mohindru, Torran Semple, Hrushikesh Divyateja, Grazziela Figueredo, Philip Quinlan, Guruprasad Padur Aithal, Srinivasan Madhusudan   +9 more
doaj   +2 more sources

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation

Frontiers in Pharmacology, 2023
Background: Awareness about the importance of implementing DPYD pharmacogenetics in clinical practice to prevent severe side effects related to the use of fluoropyrimidines has been raised over the years.
Rossana Roncato, Giuseppe Toffoli, Elena De Mattia   +2 more
exaly   +3 more sources

Integrated analysis of metabolic gene features and the immune microenvironment: identification of DPYD-mediated prognostic model and therapeutic targets in pancreatic cancer [PDF]

BMC Gastroenterology
Background Pancreatic ductal adenocarcinoma (PAAD) is a malignant digestive system tumor characterized by extremely poor prognosis and significant molecular heterogeneity. Metabolic reprogramming, a key hallmark of cancer, is considered a vital mechanism
Haoyu Bao, Bowen Pu, Shengpeng Zhu, Yongqiang Chen, Xiaohong Wang, Weihao Guo, Qikai Sun, Yeben Qian   +7 more
doaj   +2 more sources

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger [PDF]

Frontiers in Pharmacology
IntroductionFluoropyrimidines (FP) are the mainstay of colorectal cancer (CRC) treatment, but can cause severe toxicity in up to 40% of patients. Variants in the DPYD gene are associated with these adverse events.
Rocío Rosas-Alonso, Rocío Rosas-Alonso, Nuria Rodríguez Salas, Nuria Rodríguez Salas, Pablo Perez Wert, Angela Hoyo, Susana Martin-López, Daniel Martínez-Pérez, Iciar Ruiz-Gutiérrez, Diego Jiménez-Bou, Jesús Peña, Pedro Arias, Ana Custodio, Ana Custodio, Itsaso Losantos-García, Alberto M. Borobia, Alberto M. Borobia, Jaime Feliu, Jaime Feliu, Jaime Feliu, Ismael Ghanem, Ismael Ghanem   +21 more
doaj   +2 more sources

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

BMC Cancer, 2023
Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling   +16 more
doaj   +1 more source